Overcoming barriers to precision medicine in hepatocellular carcinoma
Unlike most solid tumors, hepatocellular carcinoma (HCC) has few targetable genetic mutations, limiting therapeutic options and research approaches. We have studied this extensively for HCC arising in the context of HBV infection. Using affinity purification-mass spectrometry and gene wide CRISPRi, we have found the ways that hepatitis B virus (HBV) alters protein networks and genetic dependencies. With the emergence of anti-vascular/immune therapy combinations for HCC, we are also studying the HCC contribution to response and resistance to these therapies.
1 of 4

 

The Gordan Lab is an interdisciplinary research group based in the Quantitative Biosciences Institute (QBI) at UCSF. Our research focuses on basic and translational questions in the treatment of liver cancers, combining innovative proteomic methods with unique patient-derived models to identify new therapeutic targets and markers of drug response.  We have four major areas of investigation:

1. Overcoming the barriers to precision medicine in hepatocellular carcinoma 
2. Targeting oncogenic Protein Kinase A signaling
3. Overcoming resistance to direct KRAS inhibitors in GI cancers
4. Investigating small molecule strategies to activate tumor suppressor signaling